Skip to main content
Home > Week in Review > Clinical Status

Chronological Index of : Clinical Status

 Current Issue
  • AKB-9778: Completed Phase II enrollment

    Aerpio Therapeutics Inc., Cincinnati, Ohio Product: AKB-9778 Business: Ophthalmic Molecular target: Protein tyrosine phosphatase receptor type D (PTPRD) (HPTP) beta Description: Tyrosine kinase receptor 2 (Tie2) …

    Published on 12/15/2014
  • Aldoxorubicin: Phase III hold

    CytRx Corp. (NASDAQ:CYTR), Los Angeles, Calif. Product: Aldoxorubicin (formerly DOXO-EMCH, INNO-206) Business: Cancer Molecular target: DNA Description: 6-maleimidocaproyl hydrazone prodrug of doxorubicin Indication: …

    Published on 12/15/2014
  • Anti-HER2-ADC: Phase I started

    Synthon Beta.V., Nijmegen, the Netherlands Product: Anti-HER2-ADC (SYD985) Business: Cancer Molecular target: Epidermal growth factor receptor 2 (EGFR2) (HER2) (ErbB2) (neu) Description: Antibody-drug conjugate (ADC) …

    Published on 12/15/2014
  • C-Cure: Phase III start

    Cardio3 BioSciences S.A. (Euronext:CARD), Mont-Saint-Guibert, Belgium Product: C-Cure (C3BS-CQR-1) Business: Cardiovascular Molecular target: NA Description: Cellular therapy based on autologous stem cells …

    Published on 12/15/2014
  • CL-108: Phase III started

    Charleston Laboratories Inc., Jupiter, Fla. Daiichi Sankyo Co. Ltd. (Tokyo:4568), Tokyo, Japan Product: CL-108 Business: Neurology Molecular target: NA Description: Bilayered tablet containing 12.5 mg immediate-release …

    Published on 12/15/2014
  • CL-108: Phase III started

    Charleston Laboratories Inc., Jupiter, Fla. Daiichi Sankyo Co. Ltd. (Tokyo:4568), Tokyo, Japan Product: CL-108 Business: Neurology Molecular target: NA Description: Bilayered tablet containing 12.5 mg immediate-release …

    Published on 12/15/2014
  • ELAD system: Phase III started

    Vital Therapies Inc. (NASDAQ:VTL), San Diego, Calif. Product: ELAD system Business: Hepatic Molecular target: NA Description: Human liver cell-based extracorporeal liver assist device (ELAD) Indication: Treat severe …

    Published on 12/15/2014
  • Gevokizumab: Phase III started

    Xoma Corp. (NASDAQ:XOMA), Berkeley, Calif. Servier, Neuilly-sur-Seine, France Product: Gevokizumab (S 78989, XOMA 052) Business: Dermatology Molecular target: Interleukin-1 (IL-1) beta Description: Humanized IgG2 mAb …

    Published on 12/15/2014
  • ISIS-SMNRx: Phase III started

    Isis Pharmaceuticals Inc. (NASDAQ:ISIS), Carlsbad, Calif. Product: ISIS-SMNRx Business: Neurology Molecular target: Survival of motor neuron 2 centromeric (SMN2) Description: Antisense oligonucleotide that modulates …

    Published on 12/15/2014
  • ITI-007: Phase III started

    Intra-Cellular Therapies Inc. (NASDAQ:ITCI), New York, N.Y. Product: ITI-007 Business: Neurology Molecular target: Serotonin (5-HT2A) receptor; Dopamine receptor Description: Dual serotonin (5-HT2A) receptor antagonist …

    Published on 12/15/2014
  • LY3314814: Phase II/III started

    AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Product: LY3314814, AZD3293 Business: Neurology Molecular target: Beta-site APP-cleaving enzyme 1 (BACE1); Beta-site APP…

    Published on 12/15/2014
  • MyeloXen: Phase I/IIa ongoing

    Xenetic Biosciences Inc. (OTCBB:XBIO), Lexington, Mass. Pharmsynthez JSC (MICEX:LIFE), St. Petersburg, Russia Product: MyeloXen Business: Autoimmune Molecular target: Myelin basic protein (MBP) Description: Liposomal …

    Published on 12/15/2014
  • OBE001: Phase II started

    ObsEva S.A., Geneva, Switzerland Merck KGaA (Xetra:MRK), Darmstadt, Germany Product: OBE001 Business: Genitourinary Molecular target: Oxytocin (OXT) (OT) Description: Oxytocin (OXT; OT) receptor antagonist Indication: …

    Published on 12/15/2014
  • Photofrin porfimer sodium: Phase III started

    Concordia Healthcare Corp. (TSX:CXR; OTCQX:CHEHF), Oakville, Ontario Product: Photofrin porfimer sodium Business: Cancer Molecular target: Not applicable Description: Photodynamic therapy (PDT) with porfimer light-…

    Published on 12/15/2014
  • PLX3397: Phase II start

    Daiichi Sankyo Co. Ltd. (Tokyo:4568), Tokyo, Japan Product: PLX3397 Business: Cancer Molecular target: Colony-stimulating factor 1 receptor (CSF1R) (C-FMS) (CD115); Stem cell factor (SCF) receptor tyrosine kinase (c-Kit…

    Published on 12/15/2014
  • Rocilinostat: Phase II started

    Acetylon Pharmaceuticals Inc., Boston, Mass. Product: Rocilinostat (ACY-1215) Business: Cancer Molecular target: Histone deacetylase 6 (HDAC6) Description: Oral selective histone deacetylase 6 (HDAC6) inhibitor …

    Published on 12/15/2014
  • Sustained Release Travoprost: Phase IIb started

    Ocular Therapeutix Inc. (NASDAQ:OCUL), Bedford, Mass. Product: Sustained Release Travoprost (OTX-TP) Business: Ophthalmic Molecular target: NA Description: Hydrogel-based punctum plug that delivers sustained-release …

    Published on 12/15/2014
  • TGR-1202: Phase I started

    Rhizen Pharmaceuticals S.A., La Chaux-de-Fonds, Switzerland TG Therapeutics Inc. (NASDAQ:TGTX), New York, N.Y. Product: TGR-1202 (formerly RP5264) Business: Cancer Molecular target: Phosphoinositide 3-kinase (PI3K) …

    Published on 12/15/2014
  • TRC105: Phase II started

    Tracon Pharmaceuticals Inc., San Diego, Calif. Product: TRC105 Business: Cancer Molecular target: Endoglin (CD105) (ENG) Description: Human chimeric mAb against endoglin (CD105; ENG) Indication: Treat metastatic renal …

    Published on 12/15/2014
  • VAC-3S: Phase II ongoing

    InnaVirVax S.A., Evry, France Product: VAC-3S Business: Infectious Molecular target: HIV gp41 Description: HIV gp41 peptide that inhibits reductions in CD4+ T cell count Indication: Treat HIV-1 infection Endpoint: Anti-…

    Published on 12/15/2014
  • ALT-803: Phase I/II started

    Altor BioScience Corp., Miramar, Fla. Shenzhen Beike Biotechnology Co. Ltd., Shenzhen, China Product: ALT-803 Business: Cancer Molecular target: Interleukin-15 (IL-15) Description: IL-15 mutant agonist complexed to an …

    Published on 12/8/2014
  • Ampion: Completed Phase III enrollment

    Ampio Pharmaceuticals Inc. (NYSE-M:AMPE), Englewood, Colo. Product: Ampion Business: Autoimmune Molecular target: NMDA receptor; Serotonin (5-HT2C) receptor Description: A cyclic aspartate-alanine dipeptide cleaved from…

    Published on 12/8/2014
  • Anagrelide CR: Completed Phase II enrollment

    Galena Biopharma Inc. (NASDAQ:GALE), Portland, Ore. Product: Anagrelide CR (GALE-401) Business: Hematology Molecular target: NA Description: Controlled-release formulation of anagrelide Indication: Treat …

    Published on 12/8/2014
  • AUT00063: Phase IIa started

    Autifony Therapeutics Ltd., London, U.K. Product: AUT00063 Business: Other Molecular target: Potassium channel Kv3.1 (KCNC1) Description: Oral small molecule that modulates potassium channel Kv3.1 (KCNC1) Indication: …

    Published on 12/8/2014
  • BGB324: Phase Ib started

    BerGenBio A/S, Bergen, Norway Rigel Pharmaceuticals Inc. (NASDAQ:RIGL), South San Francisco, Calif. Product: BGB324 (formerly R428) Business: Cancer Molecular target: AXL receptor tyrosine kinase (AXL) (UFO) Description…

    Published on 12/8/2014

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993